Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Certara, Inc. (CERT)
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-11-04
$11.09+2.02%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
0.39 → 0.40 EPS · FY ending Dec 31, 2027 · 5 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 6 to 5; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for CERT yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Stable leadership after CFO transition | A supporting condition in Certara, Inc.'s published investment case. The stated target is No further key executive departures in next 4 quarters. | Under Pressure | Additional key executives leave within next 4 quarters | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
CERT is a business in transition, with modest growth in software offsetting declines in services after a divestiture. Its long-term thesis is intact, supported by recent financial performance and a more favorable sector backdrop, but earnings quality remains weak because the business is loss-making.
CERT is valued at a premium to peers, and the evidence describes that valuation as expensive without the full combination of weakness and turbulence. The expectations gap suggests that valuation depends in part on a re-rating, or a change in how investors value the business, while consecutive earnings misses make that premium harder to support.
For 2026, management has reaffirmed 0% to 4% revenue growth for continuing operations, with software growth offsetting services declines. The Regulatory and Medical Writing divestiture closed as planned, while continuing-operations margin guidance is slightly lower than the prior year. Near term, recent earnings misses and the possibility of a guidance cut remain risks despite the latest earnings being in line.
The multi-year view hinges on whether modest continuing-operations growth and cost discipline can persist after the divestiture. A guidance cut or further weakening in the jobs report would add pressure, while continued earnings strength and higher guidance from healthcare peers could support the sector backdrop.
Over the next 1 to 3 years, CERT’s thesis rests on steady execution in its continuing business and evidence that sector support can offset elevated operating and earnings risks. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Profit margins should stay near 30% to 32%. |
| Intact |
| Margin falls below 30% in FY26 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 3 of 3 supplied quarters. Management reported: “• Full year 2026 adjusted EBITDA margin for Continuing Operations, excluding the Regulatory and Medical writing business, is expected to be approximately 29% to 31%.” Operating income was $-0.196 million in 2026-Q2. Delivery assessment Nov 4, 2026 |
Revenue growth of 0% to 4% excluding divested business | A primary condition in Certara, Inc.'s published investment case. The stated target is 0% to 4% growth YoY. | Under Pressure | Revenue growth falls below 0% in FY26 | Revenue growth: -10.81% FY2026-Q2; GAAP. Published target: 0% to 4% growth YoY. Annual target cannot be compared with a quarterly or TTM observation. Aug 4, 2026-10.805202 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 3 of 3 supplied quarters. Management reported: ““We continue to expect full-year revenue growth of 0% to 4% on a comparable continuing operations basis, supported by continued strength in software and improving services performance as we move through the second half of the year.”” Revenue was $93.271 million in 2026-Q2. Delivery assessment Nov 4, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.41 → $0.40 · observed estimates
$0.41B → $0.39B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $0.41 | $405,471,360 | 11 / 11 |
| 2026-07-25 | $0.41 | $405,471,360 | 11 / 11 |
| 2026-07-26 | $0.41 | $405,471,360 | 11 / 11 |
| 2026-07-27 | $0.41 | $405,471,360 | 11 / 11 |
| 2026-07-28 | $0.41 | $405,471,360 | 11 / 11 |
| 2026-07-29 | $0.41 | $405,471,360 | 11 / 11 |
| 2026-07-30 | $0.41 | $405,471,360 | 11 / 11 |
| 2026-07-31 | $0.42 | $406,065,917 | 6 / 8 |
| 2026-08-01 | $0.41 | $405,471,360 | 11 / 11 |
| 2026-08-02 | $0.41 | $405,471,360 | 11 / 11 |
| 2026-08-03 | $0.41 | $405,471,360 | 11 / 11 |
| 2026-08-04 | $0.41 | $405,471,360 | 11 / 11 |
| 2026-08-05 | $0.42 | $406,065,917 | 5 / 8 |
| 2026-08-06 | $0.42 | $406,065,917 | 5 / 8 |
| 2026-08-07 | $0.40 | $391,498,596 | 6 / 8 |
| 2026-08-08 | $0.40 | $391,498,630 | 11 / 11 |
| 2026-08-09 | $0.40 | $391,498,630 | 11 / 11 |
| 2026-08-10 | $0.40 | $391,498,630 | 11 / 11 |
| 2026-08-11 | $0.40 | $391,498,596 | 6 / 8 |
| 2026-08-12 | $0.40 | $391,498,596 | 6 / 8 |
| 2026-08-13 | $0.40 | $391,498,630 | 11 / 11 |
| 2026-08-14 | $0.40 | $391,498,596 | 6 / 8 |
| 2026-08-15 | $0.40 | $391,498,596 | 6 / 8 |
| 2026-08-16 | $0.40 | $391,498,596 | 6 / 8 |
| 2026-08-17 | $0.40 | $391,498,596 | 6 / 8 |
| 2026-08-18 | $0.40 | $391,498,596 | 6 / 8 |
| 2026-08-19 | $0.40 | $391,498,596 | 6 / 8 |
| 2026-08-20 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-08-21 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-08-22 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-08-23 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-08-24 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-08-25 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-08-26 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-08-27 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-08-28 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-08-29 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-08-30 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-08-31 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-09-01 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-09-02 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-09-03 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-09-04 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-09-05 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-09-06 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-09-07 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-09-08 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-09-09 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-09-10 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-09-11 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-09-12 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-09-13 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-09-14 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-09-15 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-09-16 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-09-17 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-09-18 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-09-19 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-09-20 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-09-21 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-09-22 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-09-23 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-09-24 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-09-25 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-09-26 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-09-27 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-09-28 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-09-29 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-09-30 | $0.39 | $389,554,266 | 6 / 8 |
| 2026-10-01 | $0.39 | $389,545,598 | 6 / 9 |
| 2026-10-02 | $0.39 | $389,545,598 | 6 / 9 |
| 2026-10-03 | $0.39 | $389,545,598 | 6 / 9 |
| 2026-10-04 | $0.39 | $389,545,598 | 6 / 9 |
| 2026-10-05 | $0.39 | $389,545,598 | 6 / 9 |
| 2026-10-06 | $0.39 | $389,545,598 | 6 / 9 |
| 2026-10-07 | $0.39 | $389,545,598 | 6 / 9 |
| 2026-10-08 | $0.39 | $389,545,598 | 6 / 9 |
| 2026-10-09 | $0.39 | $389,595,598 | 6 / 9 |
| 2026-10-10 | $0.39 | $389,595,598 | 6 / 9 |
| 2026-10-11 | $0.39 | $389,595,598 | 6 / 9 |
| 2026-10-12 | $0.39 | $389,595,598 | 6 / 9 |
| 2026-10-13 | $0.39 | $389,595,598 | 6 / 9 |
| 2026-10-14 | $0.40 | $388,537,265 | 6 / 9 |
| 2026-10-15 | $0.40 | $388,537,265 | 5 / 9 |
| 2026-10-16 | $0.40 | $388,537,265 | 5 / 8 |
| 2026-10-17 | $0.40 | $388,537,265 | 5 / 8 |
| 2026-10-18 | $0.40 | $389,145,598 | 5 / 8 |
| 2026-10-19 | $0.40 | $389,145,598 | 5 / 8 |
| 2026-10-20 | $0.40 | $388,799,765 | 5 / 8 |
| 2026-10-21 | $0.40 | $388,799,765 | 5 / 8 |
| 2026-10-22 | $0.40 | $388,799,765 | 5 / 8 |
| 2026-10-23 | $0.40 | $388,799,765 | 5 / 9 |
| 2026-10-24 | $0.40 | $388,799,765 | 5 / 9 |
| 2026-10-25 | $0.40 | $388,799,765 | 5 / 9 |
| 2026-10-26 | $0.40 | $388,799,765 | 5 / 9 |
| 2026-10-27 | $0.40 | $388,799,765 | 5 / 9 |
| 2026-10-28 | $0.40 | $388,716,432 | 5 / 9 |
| 2026-10-29 | $0.40 | $388,716,432 | 5 / 9 |
| 2026-10-30 | $0.40 | $388,716,432 | 5 / 9 |
| 2026-10-31 | $0.40 | $388,716,432 | 5 / 9 |
| 2026-11-01 | $0.40 | $388,716,432 | 5 / 9 |
| 2026-11-02 | $0.40 | $388,716,432 | 5 / 9 |
| 2026-11-03 | $0.40 | $388,716,432 | 5 / 9 |
| 2026-11-04 | $0.40 | $388,716,432 | 5 / 9 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 4 Buy / Strong Buy · 9 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 3 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.